Please login to the form below

Not currently logged in
Email:
Password:

Generics UK

This page shows the latest Generics UK news and features for those working in and with pharma, biotech and healthcare.

Warning ‘at red’ on no deal Brexit medicines chaos

Warning ‘at red’ on no deal Brexit medicines chaos

The UK pharma, biotech and generics medicines associations and the NHS’ Brexit Health Alliance and others have now called for an urgent meeting with the health secretary Matt Hancock, and say ... The EU says an agreement must be reached by the

Latest news

  • Lilly wins on appeal in Alimta vitamin regimen dispute Lilly wins on appeal in Alimta vitamin regimen dispute

    The ruling finds that Actavis generics on sale in the UK, France, Italy and Spain infringe on Lilly's patents for Alimta (pemetrexed disodium), which has lost patent protection in several ... directly infringe the patents, a decision which was upheld the

  • Teva sells UK and Ireland assets to Intas Pharma for £603m Teva sells UK and Ireland assets to Intas Pharma for £603m

    Generics portfolio and manufacturing facility gain set to double Indian firm’s UK sales. ... Offloading Actavis Generics UK and Irish assets is the latest in a series of divestments by Teva to meet antitrust conditions from international regulatory

  • Lundbeck challenge to EC pay-for-delay ruling fails Lundbeck challenge to EC pay-for-delay ruling fails

    Court upholds 94m fine for paying off firms to delay launch of Celexa generics. ... The four generics companies - Generics UK, Arrow, Alpharma and Ranbaxy - were fined around 52m, and those judgments have also been upheld by the General Court of the EU.

  • UK government fines GSK over 'pay-for-delay' deals UK government fines GSK over 'pay-for-delay' deals

    Actavis which have both been fined for the involvement of various generics units. ... Former Merck subsidiary Generics (UK) Ltd and Alpharma (acquired by Actavis in 2005) had been sued by GSK for patent infringement but the cases were dropped after the

  • No further price cut for non-PPRS drugs in UK No further price cut for non-PPRS drugs in UK

    Questions were also raised by the British Generic Manufacturers' Association (BGMA), which represents manufacturers and suppliers of generic drugs in the UK. ... Also weighing in was the Ethical Medicines Industry Group, representing the smaller drug

More from news
Approximately 3 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • Mylan sees the UK paving the way for an insulin game changer Mylan sees the UK paving the way for an insulin game changer

    The fertile UK landscape is an alluring springboard for biosimilars, with Mylan recording strong uptakes in previous launches. ... biosimilars. “The UK can take the lead on showing other countries how to properly manage the opportunity of

  • Deal Watch October 2016 Deal Watch October 2016

    Similarly the acquisition of Actavis (Allergan) Generics by Teva for $40.5bn has resulted in the divestment of Actavis's former factory and some products in the UK and Ireland to ... Teva (IS). Intas (IN). Asset Acquisition. Former Actavis generics

  • Pharma deals during January 2015 Pharma deals during January 2015

    This deal was of significance to Actavis as it gives the company the number 1 position for generics in the UK.

  • Proving value in uncertain times Proving value in uncertain times

    Additional pressure is being exerted in many EU markets with the introduction of new, additional barriers to access, whether it's the idea of value-based pricing in the UK or ... officially sanctioned generics prescribing targets in markets such as Spain,

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Teva appoints UK & Ireland general manager Teva appoints UK & Ireland general manager

    Promotes UK chief operating officer Kim Innes. Teva UK has promoted chief operating officer Kim Innes to general manager of its UK and Ireland business, succeeding Richard Daniell. ... She became head of Teva's generics business unit in the UK in 2006,

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

We're award-winning joint working specialists. We help our clients to transform healthcare through effective collaboration, and deliver work to feel...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics